The role of Thr139 in the human immunodeficiency virus type 1 reverse transcriptase sensitivity to (+)-calanolide A

被引:14
|
作者
Auwerx, J
Rodríguez-Barrios, F
Ceccherini-Silberstein, F
San-Félix, A
Velázquez, S
De Clercq, E
Camarasa, MJ
Perno, CF
Gago, F
Balzarini, J
机构
[1] Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium
[2] Univ Alcala de Henares, Dept Pharmacol, Alcala De Henares, Spain
[3] Univ Roma Tor Vergata, Dept Expt Med, Rome, Italy
[4] CSIC, Inst Quim Med, E-28006 Madrid, Spain
关键词
D O I
10.1124/mol.105.012351
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The coumarins represent a unique class of non-nucleoside reverse transcriptase inhibitors (NNRTIs) that were isolated from tropical plants. (+)-Calanolide A, the most potent compound of this class, selects for the T139I resistance mutation in HIV-1 reverse transcriptase (RT). Seven RTs mutated at amino acid position 139 (Ala, Lys, Tyr, Asp, Ile, Ser, and Gln) were constructed by site-directed mutagenesis. The mutant T139Q enzyme retained full catalytic activity compared with wild-type RT, whereas the mutant T139I, T139S, and T139A RTs retained only 85 to 50% of the activity. Mutant T139K, T139D, and T139Y RTs had seriously impaired catalytic activities. The mutations in the T139I and T139D RTs were shown to destabilize the RT heterodimer. (+)-Calanolide A lost inhibitory activity (up to 20-fold) against the mutant T139Y, T139Q, T139K, and T139I enzymes. All of the mutant enzymes retained marked susceptibility toward the other NNRTIs, including nevirapine, delavirdine, efavirenz, thiocarboxanilide UC-781, quinoxaline GW867420X, TSAO [[2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5 ''-(4 ''-amino-1 '',2 ''-oxathiole-2 '',2 ''-dioxide)]derivatives, and the nucleoside inhibitor, ddGTP. The fact that the T139I RT 1) proved to be resistant to (+)-calanolide A, 2) represents a catalytically efficient enzyme, and 3) requires only a single transition point mutation (ACA -> ATA) in codon 139 seems to explain why mutant T139I RT virus strains, but not virus strains containing other amino acid changes at this position, predominantly emerge in cell cultures under (+)-calanolide A pressure.
引用
收藏
页码:652 / 659
页数:8
相关论文
共 50 条
  • [1] Kinetic analysis of inhibition of human immunodeficiency virus type-1 reverse transcriptase by calanolide A
    Currens, MJ
    Mariner, JM
    McMahon, JB
    Boyd, MR
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1996, 279 (02): : 652 - 661
  • [2] Human immunodeficiency virus type 1 reverse transcriptase
    Hottiger, M
    Hubscher, U
    BIOLOGICAL CHEMISTRY HOPPE-SEYLER, 1996, 377 (02): : 97 - 120
  • [3] Chimeric human immunodeficiency virus type 1 and feline immunodeficiency virus reverse transcriptases: Role of the subunits in resistance/sensitivity to non-nucleoside reverse transcriptase inhibitors
    Auwerx, J
    North, TW
    Preston, BD
    Klarmann, GJ
    De Clercq, E
    Balzarini, J
    MOLECULAR PHARMACOLOGY, 2002, 61 (02) : 400 - 406
  • [4] Purification and characterization of human immunodeficiency virus type 1 reverse transcriptase
    LeGrice, SFJ
    Cameron, CE
    Benkovic, SJ
    DNA REPLICATION, 1995, 262 : 130 - 144
  • [5] Recombinant human immunodeficiency virus type 1 reverse transcriptase is heterogeneous
    Wilson, JE
    Wright, LL
    Martin, JL
    Haire, SE
    Ray, PH
    Painter, GR
    Furman, PA
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1996, 11 (01): : 20 - 30
  • [6] Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase
    Sharma, PL
    Nurpeisov, V
    Hernandez-Santiago, B
    Beltran, T
    Schinazi, RF
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2004, 4 (09) : 895 - 919
  • [7] A role for dNTP binding of human immunodeficiency virus type 1 reverse transcriptase in viral mutagenesis
    Weiss, KK
    Chen, RX
    Skasko, M
    Reynolds, HM
    Lee, K
    Bambara, RA
    Mansky, LM
    Kim, B
    BIOCHEMISTRY, 2004, 43 (15) : 4490 - 4500
  • [8] Dimerization of human immunodeficiency virus type 1 reverse transcriptase as an antiviral target
    Srivastava, S.
    Sluis-Cremer, N.
    Tachedjian, G.
    CURRENT PHARMACEUTICAL DESIGN, 2006, 12 (15) : 1879 - 1894
  • [9] Mutations that abrogate human immunodeficiency virus type 1 reverse transcriptase dimerization affect maturation of the reverse transcriptase heterodimer
    Wapling, J
    Moore, KL
    Sonza, S
    Mak, J
    Tachedjian, G
    JOURNAL OF VIROLOGY, 2005, 79 (16) : 10247 - 10257
  • [10] Unique anti-human immunodeficiency virus activities of the nonnucleoside reverse transcriptase inhibitors calanolide A, costatolide, and dihydrocostatolide
    Buckheit, RW
    White, EL
    Fliakas-Boltz, V
    Russell, J
    Stup, TL
    Kinjerski, TL
    Osterling, MC
    Weigand, A
    Bader, JP
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (08) : 1827 - 1834